Why the study?
The cardioprotective effects of nebivolol compared with metoprolol against LPS-induced injury in H9c2 cardiomyoblasts had not been investigated.
Does nebivolol compared to metoprolol improve LPS-induced cytotoxicity, oxidative stress, and inflammation in H9c2 cardiomyoblasts?
Does nebivolol compared to metoprolol improve LPS-induced cytotoxicity, oxidative stress, and inflammation in H9c2 cardiomyoblasts?
Nebivolol offers superior anti-inflammatory and mitochondrial fusion-promoting effects compared to metoprolol in an in vitro model of LPS-induced cardiomyoblast injury.
May differentiate nebivolol from metoprolol for inflammatory cardiomyocyte injury; hypothesis-generating and requires in vivo validation.
Here, we, for the first time, compared the cardioprotective effects of third-generation vasodilating beta-blocker nebivolol (Neb) and conventional beta-blocker metoprolol (Met) on LPS-induced injury in H9c2 cardiomyoblasts. Our findings denoted that Neb and Met pretreatment diminish LPS-mediated cytotoxicity and oxidative stress. Concomitantly, LPS-triggered inflammatory cytokines activation was significantly suppressed by Neb but not by Met. Pretreatment with either Neb or Met alleviated LPS-mediated mitochondrial impairment by enhancing the expression of genes related to its biogenesis such as PGC-1α, NRF1, and TFAM. On the contrary, Neb but not Met-upregulated mitochondrial fusion-related genes such as OPA, and MFN2. In summary, our findings suggest that Neb and Met treatment significantly ameliorated the LPS-induced cytotoxicity and oxidative stress. Additionally, these findings suggest that Neb but not Met significantly down-regulates LPS-induced proinflammatory factors, probably by enhancing mitochondrial biogenesis and fusion.
No takes yet. Share an insight, caveat, or question.
Gul et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: